IDEAYA Biosciences/$IDYA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About IDEAYA Biosciences
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Ticker
$IDYA
Sector
Primary listing
Employees
131
Headquarters
Website
IDYA Metrics
BasicAdvanced
$2.8B
-
-$1.82
0.05
-
Price and volume
Market cap
$2.8B
Beta
0.05
52-week high
$33.64
52-week low
$13.45
Average daily volume
1.2M
Financial strength
Current ratio
12.443
Quick ratio
12.198
Long term debt to equity
2.465
Total debt to equity
2.495
Profitability
EBITDA (TTM)
-206.33
Gross margin (TTM)
-71.43%
Net profit margin (TTM)
-74.82%
Operating margin (TTM)
-97.23%
Revenue per employee (TTM)
$1,640,000
Management effectiveness
Return on assets (TTM)
-10.77%
Return on equity (TTM)
-14.15%
Valuation
Price to revenue (TTM)
13.115
Price to book
2.56
Price to tangible book (TTM)
2.56
Price to free cash flow (TTM)
-26.733
Free cash flow yield (TTM)
-3.74%
Free cash flow per share (TTM)
-1.195
Growth
Revenue change (TTM)
5,377.66%
Earnings per share change (TTM)
-22.16%
3-year revenue growth (CAGR)
62.71%
3-year earnings per share growth (CAGR)
10.47%
What the Analysts think about IDYA
Analyst ratings (Buy, Hold, Sell) for IDEAYA Biosciences stock.
Bulls say / Bears say
FDA granted Breakthrough Therapy designation for darovasertib in neoadjuvant uveal melanoma, expediting development and priority review (PRNewswire).
IDEAYA completed a successful FDA Type D meeting finalizing the Phase 3 registrational trial design for neoadjuvant darovasertib, establishing a clear path to potential approval (PRNewswire).
As of June 30, 2025, IDEAYA held $991.9 million in cash and equivalents, providing runway into 2029 to advance its clinical pipeline (GuruFocus).
IDEAYA reported a Q2 net loss of $77.5 million and EPS of -$0.88, missing the consensus estimate of -$0.80 and reflecting ongoing high cash burn (GuruFocus).
The company generated no revenue in Q2 2025, missing the estimated $3.23 million target and highlighting lack of commercialization progress (GuruFocus).
Key median PFS data from the Phase 2/3 darovasertib + crizotinib trial in first-line metastatic uveal melanoma is not expected until year-end 2025, potentially delaying accelerated approval and revenue generation (PRNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
IDYA Financial Performance
Revenues and expenses
IDYA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IDEAYA Biosciences stock?
IDEAYA Biosciences (IDYA) has a market cap of $2.8B as of November 14, 2025.
What is the P/E ratio for IDEAYA Biosciences stock?
The price to earnings (P/E) ratio for IDEAYA Biosciences (IDYA) stock is 0 as of November 14, 2025.
Does IDEAYA Biosciences stock pay dividends?
No, IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders as of November 14, 2025.
When is the next IDEAYA Biosciences dividend payment date?
IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders.
What is the beta indicator for IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) has a beta rating of 0.05. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.